Root Financial Partners’s Entrada Therapeutics TRDA Stock Holding History

Root Financial Partners’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$597	Buy	+94	New	+$652	﹤0.01%	3157

Other funds holding TRDA

Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

PWMG

Private Wealth Management Group Princeton, New Jersey $445M AUM 13.54% 1-Year Est. Return

Root Financial Partners's TRDA Position: Q3 2026 in Review

Root Financial Partners opened a new position in Entrada Therapeutics (TRDA) in Q3 2026: 94 shares worth $597. The stake represents ﹤0.01% of the portfolio and ranks #3157 among its holdings.

14 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.

Root Financial Partners held 94 shares of Entrada Therapeutics worth $597 as of Q3 2026.
Entrada Therapeutics was a new Root Financial Partners position in Q3 2026.
Entrada Therapeutics made up ﹤0.01% of Root Financial Partners's portfolio in Q3 2026, its #3157 holding.
14 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.

Based on Root Financial Partners's 13F filing for Q3 2026, filed 21 Oct 2026.